ACT Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

ACT Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$1.78M	Sell	120,400 -106,200	-47%	-$1.78M	2.46%	12
2022 Q2	$3.57M	Sell	226,600 -26,700	-11%	-$524K	4.99%	6
2022 Q1	$6.83M	Sell	253,300 -226,100	-47%	-$5.77M	7.23%	3
2021 Q4	$17.7M	Buy	479,400 +24,100	+5%	+$982K	12.83%	2
2021 Q3	$21.8M	Hold	455,300	–	–	11.27%	2
2021 Q2	$15.4M	Buy	+455,300	New	+$15.4M	7.92%	3

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

ACT Capital Management's ARCT Position: Q3 2022 in Review

ACT Capital Management reduced its Arcturus Therapeutics (ARCT) stake by 47% in Q3 2022, selling an estimated $1.78M and leaving 120,400 shares worth $1.78M. The position accounts for 2.46% of the portfolio, ranked #12.

ACT Capital Management first reported a position in ARCT in Q2 2021 and has held it in 6 quarters since. The position peaked at $21.8M in Q3 2021. 116 funds tracked by Wall St. Rank hold ARCT as of Q3 2022.

ACT Capital Management held 120,400 shares of Arcturus Therapeutics worth $1.78M as of Q3 2022.
ACT Capital Management sold 106,200 Arcturus Therapeutics shares in Q3 2022, an estimated $1.78M.
Arcturus Therapeutics made up 2.46% of ACT Capital Management's portfolio in Q3 2022, its #12 holding.
ACT Capital Management first reported a position in Arcturus Therapeutics in Q2 2021 and has held it in 6 quarters since.
ACT Capital Management's Arcturus Therapeutics position peaked at $21.8M in Q3 2021.
116 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2022.

Based on ACT Capital Management's 13F filing for Q3 2022, filed 3 Nov 2022.